Latest Headlines

  1. SCYNEXIS And Trevena Announce Strategic Collaboration To Enhance Discovery Of Biased GPCR Ligands
    5/19/2010
    SCYNEXIS, Inc. a drug discovery and development company, and Trevena, Inc., a leader in the discovery and development of G-protein coupled receptor (GPCR) biased ligands, announced recently that they have entered into an agreement in which SCYNEXIS will provide medicinal chemistry services to support Trevena's ongoing research activities directed at the discovery of biased GPCR ligands. The terms of the agreement were not disclosed.
  2. Allos Therapeutics’ Pralatrexate Granted FDA Orphan Drug Designation For The Treatment Of Bladder Cancer
    5/18/2010
    Allos Therapeutics, Inc. (Nasdaq: ALTH) announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to pralatrexate for the treatment of advanced or metastatic transitional cell carcinoma (TCC) of the urinary bladder, a form of bladder cancer.
  3. Compugen Discovers Drug Target For Treatment Of Multiple Myeloma
    5/11/2010
    Compugen Ltd. (NASDAQ: CGEN) announced today the discovery and initial experimental validation of CGEN-928 as a drug target for the treatment of multiple myeloma.
  4. Vicor Technologies Receives Allowance Of United States Patent Application Related To Its State Dependent Drug Development Platform
    5/6/2010
    David H. Fater, CEO of Vicor Technologies, Inc. (OTCBB: VCRT), today announced the Company received a Notice of Allowance for its U.S. Patent Application No. 10/359,363 for a method of treating ischemia through administration of a biologic identified through Vicor's state dependent drug discovery platform
  5. Fluxion Biosciences Announces Opening Of 2010 BioFlux Innovation Award
    5/5/2010
    Fluxion Biosciences, a leading developer of microfluidic systems for functional cell analysis, today announced the launch of its 2010 BioFlux Innovation Award. This program allows scientists from all around the world to submit innovative research ideas using the BioFlux system for live cell imaging under controlled physiological flow conditions
  6. Massachusetts Institute Of Technology (MIT) Joins Pool For Open Innovation Against Neglected Tropical Diseases
    5/5/2010
    The Massachusetts Institute of Technology (MIT) recently became the first academic institution to contribute intellectual property to the Pool for Open Innovation against Neglected Tropical Diseases
  7. ACADIA Pharmaceuticals To Present At The Ninth Annual JMP Securities Research Conference On May 12, 2010
    5/5/2010
    ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, recently announced that it will present at the Ninth Annual JMP Securities Research Conference on Wednesday, May 12, 2010 at 11:00 a.m.
  8. EMD Serono, Inc. And FAST FORWARD, LLC Announce First Results of Their Collaboration To Advance Drug Development In Multiple Sclerosis
    5/5/2010
    EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt Germany, and Fast Forward, LLC, a not-for-profit organization established by the National Multiple Sclerosis Society to accelerate the development of discoveries into new or improved therapies, today announced the first four recipients of funding designed to speed research advances in mutually selected high potential areas of MS research. The awards total nearly $1.5 million.
  9. Asterand Signs Agreement With Eisai Co., Ltd
    5/4/2010
    Asterand plc , a leading provider of human tissue and human tissue-based services to pharmaceutical and biotechnology companies engaged in drug discovery, recently announces that its subsidiary BioSeek, LLC, a pioneer in the application of predictive human biology to drug discovery, has signed a two-year collaboration agreement with Eisai Co., Ltd., a research-based human health care company headquartered in Japan
  10. TGR BioSciences Announces Expansion Of Its ‘No-Wash’ SureFire Cellular Kinase Assay Portfolio
    5/3/2010
    TGR BioSciences announces expansion of the extremely successful and proven ‘No-wash' SureFire portfolio by addition of 9 new cell pathway analysis kits for measurement of phospho-proteins

First 3 4 5 6 7 8 9 10 10 (Last)